To determine the costs associated with antidepressant (AD) use by depression and anxiety status in a public-managed health care system.
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Clinical Implications
• Overall, the use of ADs was associated with higher health care costs in older adults who showed no symptoms of anxiety or depression.
• AD use was not associated with reduced costs in respondents with persistent depression and anxiety.
Limitations
• Mental health status was based on self-reported data and not confirmed by clinical interview.
• Costs were not studied as a function of adequacy of AD treatment in relation to depression and anxiety status.
• Results were based on an observational study design and not a randomized clinical trial.
D uring the past decades, like other Western countries, Canada has seen an exponential rise in AD sales, with costs rising from $31.4 million in 1981 to $543 million in 2000. 1 In the older adult population, also in Canada, Mamdani et al 2 reported a 210% increase in total expenditures on psychotropics from 1993 to 2002. Among the $149 million reached during the period, ADs accounted for 42%. The reported rate of AD use doubled from 5.6% in 1993 to 10.9% in 2002. 2 In the older adult population, depression and anxiety are the most common affective disorders, 3 and are associated with important comorbidity, [4] [5] [6] higher rates of falls, 7 suicide, 8 and mortality, 9, 10 as well as increased health care service use and associated costs. [11] [12] [13] [14] [15] [16] ADs are generally considered the first-line treatments for these disorders and are thus, not surprisingly, among the most commonly used psychotropics. 17 However, recent reviews have shown inconsistent findings regarding the cost-effectiveness of AD treatments for mild and moderate depression and urge further studies in real-world settings. [18] [19] [20] [21] Because depression and anxiety may not be validly measured in administrative databases, numerous epidemiologic and cost studies use therapy adherence or persistence rate as measures of disorder resolution. [22] [23] [24] [25] [26] To date, little is known about the clinical characteristics and the health care costs associated with the remission or persistence of depressive and anxiety symptoms in AD users in real-world settings, in the older adult population.
Our study aimed to assess the health care costs associated with AD use and change in status regarding the presence of depression and anxiety measured at 2 time points, 1 year apart, in a large representative community-dwelling older adult cohort in a public-managed health care system. Administrative health service data were linked to self-reported data, increasing the validity of measures. Controlling for numerous sociodemographic and economic variables, as well as physical status, our study estimates the economic impact associated with AD treatment for depression and anxiety.
Methods
Study Sample
Our study was based on data collected in the ESA survey on the health of the elderly conducted in 2005 to 2006 using a probabilistic sample of the community-living older adult population aged 65 years and older in Quebec. The method of random digit dialing was used to develop the study sampling frame that considered regions stratified according to 3 types of geographical areas, based on population centres and rural regions: according to the Quebec Institute of Statistics. The response rates at baseline and at the 12-month follow-up interview were 76.5% and 79.1%, respectively.
Data Collection
A nurse contacted potential participants by telephone to present the objectives of our study and solicit their participation in an in-home interview within 2 weeks and then again 12 months later.
To increase the validity of the information provided, respondents presenting severe or moderate cognitive problems based on the Mini-Mental State Examination (less than 22) 27 were excluded at the beginning of the interview. Respondents who completed the ESA questionnaire, at the end of the interview, were asked to provide written informed consent for the research team to access their health and pharmaceutical services use data from the RAMQ (Quebec's health insurance plan agency) for the year prior and following the interview. The self-reported data from the ESA survey were linked to individual-level information from the RAMQ's medical and pharmaceutical services databases and from the health ministry's MED-ÉCHO database on hospitalizations using the respondents' health insurance number or, when this number was missing, using the name, sex, address, as well as the respondents' month and year of birth. A success rate of 99.6% (n = 2494) was obtained in the matching of the data. The study protocol was reviewed and approved by the ethics committee of the University of Sherbrooke.
Measures
The respondent's past-year mental health status was measured, at baseline and at 12 months follow-up, using a computer-assisted questionnaire. The presence of a pastyear mental disorder was based on DSM-IV criteria 28 for depression and anxiety.
Depression. Participants who presented with either a depressed mood or loss of interest or pleasure in usual daily activities nearly every day and most of the day during at least 2 consecutive weeks, who also reported impairment in at least 1 area of social functioning, and who reported at least 5 of the 7 associated symptoms of depression, were classified as having MDD. Participants who presented with the essential features of depression and reported anywhere between 2 and 4 of the 7 associated symptoms of depression were classified as having minor depression. Participants whose symptoms were due to a physical disease, drug addiction, or to the loss of a loved one (grief) were not considered as having depression.
Anxiety Disorder. Participants presenting DSM-IV criteria for panic disorder, agoraphobia, generalized anxiety disorder, obsessive-compulsive disorder, or social and specific phobia during the preceding year and who reported impairment in at least one area of social functioning were classified as having anxiety. People attributing their symptoms to a physical health disease were not considered as having anxiety.
Among the 2494 participants in our study, 2004 responded to both interviews (80.3%). Respondents who completed the second interview did not differ from those who did not about sex (P = 0.93), age (P = 0.77), marital status (P = 0.15), having attained post-secondary education (P = 0.17), living in a rural area (P = 0.74), self-perceived mental health (P = 0.82), and on the probable presence of depression (P = 0.38) or anxiety (P = 0.47) at baseline. However, subjects who did not complete the second interview were less likely to belong to the higher income category (P ≤ 0.01) and less likely to report fewer than 3 chronic conditions at baseline (P ≤ 0.01). These participants were also more likely to have lower total health care costs than participants who completed the second interview (P < 0.001). Three per cent of respondents who did not complete the followup interview had died. They were more likely to be males (P = 0.02), older (P < 0.001), and have 3 chronic conditions or more (P = 0.007), but not more likely to have been diagnosed with depression or anxiety at baseline. AD use was identified from the RAMQ pharmaceutical services registry, which includes data for each Quebec resident with public drug insurance. Among the 2004 participants who responded to both interviews, 1869 were covered by the public drug plan for the 2-year study period. The RAMQ files hold for every person; every drug dispensed; the quantity, dosage, and duration; and the date the prescription was filled. The following types of ADs were found: SSRIs (for example, citalopram, fluoxetine, and paroxetine,); serotonin antagonist and reuptake inhibitor (for example, trazodone and nefadozone); SNRI (for example, venlafaxine); norepinephrine and serotonin modulators (for example, mirtazapine); norepinephrine and dopamine reuptake inhibitors; and TCAs (for example, amitriptyline and clomipramine). A participant was classified as being an AD user if they reported having filled at least 1 AD prescription at baseline interview and during the 12-month follow-up period.
Cost Data
The cost analysis in our study was carried out from both the health care system and patient perspectives. Annual costs presented are those incurred in the year following the baseline interview. Measurement and costing of resources were based on published guidelines for economic evaluations. 29 Total health care costs included inpatient stays, ED visits, outpatient visits, physician fees, and outpatient medications. Health service use was identified from the RAMQ and MED-ÉCHO databases. The RAMQ physician services database contains all claims for consultations, medical services rendered, and physician fees paid out by Quebec's medicare system. The RAMQ pharmaceutical services database, in addition to what was described above, also contains for each drug dispensed, the cost of the drug (including any copayment) and dispensing fee. The RAMQ provides information on ED visits without inpatient stays and the MED-ÉCHO database provides information on inpatient stays, and ED visits prior to hospitalizations, such as diagnoses, hospital length of stay, and services provided. A hospitalization was valued based on a cost per day and an ED visit as a cost per visit. Outpatient visits in public institutions, identified from the RAMQ database, were also valued at a cost per visit. The calculation of unit health care costs has been reported in detail elsewhere. 30 Costs considered from the patient perspective included drug copayments and those for transportation and the time spent by patients while seeking outpatient medical care. Drug copayments (costs paid out by respondents) were obtained from the RAMQ pharmaceutical database. The distance travelled by participants to and from their residence for medical care was valued based on vehicle rates used to calculate travel expenses reported by the Canada Revenue Agency 2010 reports 31 estimated at $0.565/km for the province of Quebec. For outpatient and inpatient visits, an average time of 2 hours and 1 working day (8 hours), respectively, were considered, and has been reported elsewhere. 32 The time spent was valued based on nonremunerated work estimated to be $7.50/hour by Stephens and Joubert, 33 which based on an average annual inflation of 3% brings this value to $10.69/hour in 2010.
Analyses
The 1869 respondents who participated in both interviews were grouped into 4 categories: no depression or anxiety at either interview; persistent: presence of either depression or anxiety at both interviews; remission: presence of either depression or anxiety at baseline but not at follow-up interview; and incident: presence of either depression or anxiety at follow-up but not at baseline interview. Mental health status was considered as a function of the following study variables: age, sex, education (primary, secondary, or post-secondary), marital status (married, compared with separated, divorced, widowed, or never married), income (less than $15 000 and $15 000 and more), region of residence (rural, compared with urban or metropolitan), number of chronic conditions (0 to 2 and 3 or more), and AD use (yes or no). Chi-square tests for the difference in proportions were carried out.
To account for the nonnormal distribution of costs, generalized linear models with a gamma distribution and log link 34 were estimated to describe the association between total health care costs and AD use, controlling for the presence of depression and anxiety, at baseline and at follow-up. Secondary analyses were also restricted by mental health status and to AD users. In analyzing our data, we used a one-part model 35 where all respondents were included in the analyses irrespective of whether they used a service. Regression analyses were also carried out to adjust for sociodemographic, clinical variables, and adherence to ADs measured by the medication possession ratio for the three 6-month periods. The medication possession ratio represents the ratio between the number of days an AD was supplied and the number of days corresponding to the follow-up period. Many have defined a good 6-month adherence measure as 80% or more. 36 Data were weighted to ensure that the true proportion of older adults within each of the regions and geographical areas were reflected in the analysis. 37-39 SAS version 9.1 (SAS Institute Inc, Cary, NC) was used for all statistical analyses.
Results
Overall, 9.8% (n = 184) of respondents presented with a probable MDD or minor depression meeting DSM-IV criteria at either interview, and 7.2% (n = 134) with at least one anxiety disorder. Among these, 2.1% (n = 39) presented with both anxiety and depression at either interview. The rate of AD use reached 17.8%, with the most commonly prescribed being the SSRIs (40%) followed by TCAs (23%) and SNRIs (20%). The study population respondents differed on numerous sociodemographic and clinical factors according to depression and anxiety status at baseline and at follow-up (Table 1) .
Overall, the results showed significantly higher adjusted government-borne health care costs (adjusted difference = $1711; 95% CI $67 to $3491), patient costs (adjusted difference = $274; 95% CI $45 to $503), and total costs (adjusted difference = $1980; 95% CI $44 to $3916) associated with AD use ( Table 2 ). The costs associated with mental health status restricted by depression and anxiety status are presented in Table 3 . The results show higher costs associated with AD use among respondents with no depression (adjusted difference = $1769; 95% CI $236 to $3702) and no anxiety only (adjusted difference = $1845; 95% CI $203 to $3486). The costs associated with mental health status restricted by AD use are presented in Table 4 .
Discussion
The overall annual prevalence of AD use in the older adult population reached 17.8%. An earlier time trend population study 2 in Canada showed significant increases in AD use in older adults, ranging from 5.6% to 10.9% between 1993 and 2002. Annual estimates in the United States from the Medical Panel Expenditure Survey, 40 also showed similar estimates of AD use in older adults reaching 13.7% in 2005. In Europe, the ESEMeD study 41 reported overall past-year prevalence rates of AD use reaching 34.4%. The ESEMeD study also showed that older adults were up to 6.5 times more likely to be prescribed an AD than their younger counterparts. We also observed in our study that among respondents with reported depression and anxiety, at either interview, 38.4% and 33.3%, respectively, were dispensed an AD. Similarly, the ESEMeD study also showed that close to 30% of respondents with depression had been taking ADs. 41 In the United States, the rate of AD use among older adults with depression in the past year has been reported as even higher, with levels of 63.1% in 2000 and 56.7% in 2004. 42 In our study, the most common ADs prescribed were those in the SSRI class (40%) followed by TCAs (23%), a finding similar to those reported elsewhere. 2, 42 We also observed that 14% of respondents not meeting DSM-IV criteria for depression and anxiety in the past year were also dispensed an AD. This represents 70% of respondents among AD users. Beck et al 43 also showed similar results, where 60% of AD adult users did not fill criteria for pastyear depression, but most had reported a lifetime presence of depression and anxiety. (17) 21 (50) 14 (22) 10 ( Anxiety disorder included generalized anxiety disorder, n = 28 (1.4%); panic disorder, n = 14 (0.7%); specific phobia, n = 44 (2.2%); social phobia, n = 2 (0.1%); agoraphobia, n = 4 (0.2%); and obsessive-compulsive disorder, n = 27 (1.3%).
Table 1 Characteristics of study sample based on depression and anxiety disorder status
Compared with recent studies, 24, 44 which focus on the costs relative to the persistence of medication used as a proxy for measure for the persistence of depression, we had the advantage of linking administrative health survey data to survey data on physical and mental health status at 2 time points, 1 year apart, which permitted the measure of the persistence of depression and anxiety in this older adult population.
In our study, the adjusted costs incurred by participants using ADs totalled, on average, $6678 (95% CI $5498 to $8182), which was significantly higher than total costs incurred by patients not using ADs $4698 (95% CI $3710 to $5949). Among AD users, the highest cost was associated with the use of SNRIs at $9163 (95% CI $6928 to $12 117) (adjusted difference = $3526; Wald χ 2 = 12.54, df = 1, P < 0.001), consistent with previous results. 24 A recent study 45 Our study showed that AD use was associated with increased total adjusted costs in respondents not filling criteria for depression and anxiety, and this was after controlling for adherence, as well as numerous sociodemographic and clinical factors. Looking into the different health care costs, the results showed that AD use was associated with increased outpatient visits in people not reporting depression and 
.60, df = 1, P = 0.002 χ 2 = 14.47, df = 1, P < 0.001 χ 2 = 10.79, df = 1, P = 0.001 a Adjusted for age, sex, revenue, rural region, number of chronic conditions, depression and anxiety status, and medication possession ratios. b The goodness of fit statistics for the adjusted models were 1.24, 1.24, and 1.22 for the scaled deviance and 1.65, 1.65, and 1.79 for the scaled Pearson χ 2 , respectively. Overall, the gamma distribution fit the data well as the goodness of fit listing in the outputs were close to one. Lack of fit increases as the value or degrees of freedom for scaled deviance and scaled Pearson chi-square deviate increasingly from one. The goodness of fit statistics for the adjusted cost models for depression were 1.22, 1.42, 1.32, and 2.13 for the scaled deviance and 1.76, 1.34, 1.61, and 2.51 for the scaled Pearson χ 2 , respectively. The goodness of fit statistics for the adjusted cost models for anxiety were 1.23, 1.57, 1.37, and 2.02 for the scaled deviance and 1.77, 1.07, 1.27, and 1.76 for the scaled Pearson χ 2 , respectively. Overall, the gamma distribution fit the data well as the goodness of fit listing in the outputs were close to one. Lack of fit increases as the value or degrees of freedom for scaled deviance and scaled Pearson chi-square deviate increasingly from one.
Table 3 Total adjusted costs associated with AD use by depression and anxiety status
anxiety. The increased outpatient care may be associated with the prescription of ADs and follow-up for response to treatment and management of AD secondary effects, which has also been reported in the literature. 46 Conversely, the increased outpatient costs may be due to the insufficiency of ADs to overcome the effects of chronic symptoms of depression or anxiety, which require increased outpatient care. The ADs themselves of course also contribute to total costs.
When looking at respondents using ADs (n = 332), we observed significantly higher total adjusted costs for respondents with incident depression and lower total adjusted costs for respondents with incident anxiety, compared with respondents without depression or anxiety. The greater costs observed for incident depression are associated primarily with increased hospitalization costs during the study period. Although we adjusted for the number of chronic conditions reported at baseline, hospitalizations may reflect new illness episodes (for example, acute myocardial infarction), which have been shown to trigger depression. 47 Recently, using a large administrative drug database, Milea et al 48 similarly reported, with the exception of respondents with incident anxiety and depression, that AD users without a diagnosis of a mental disorder had similar baseline costs to those with either a depressive or anxiety disorder.
Overall, the findings of our study highlight the point that there are no cost savings associated with AD use in respondents in remission and with incident or persistent depression and anxiety. The treatment of these disorders with ADs does not appear to be associated with a reduction in the costs associated with depression and anxiety, as previously reported. 49 A recent study 50 suggested that the successful cessation of ADs for depression in respondents in remission can lead to significant reductions in health service use and cost savings to the health system. Our findings also suggest that this possibility needs to be further explored. However, we cannot tell from our data whether the costs of respondents who had been depressed and taking ADs at some point in their lifetime prior to our study are comparable with those respondents who were never depressed or on ADs.
Our study presents numerous significant strengths. First, it relies on a unique dataset, linking data from standardized questionnaires with extensive administrative data on health service use and costs. As a result, determination of depression and anxiety status is much more reliable than from billing data alone. Second, the administration of standardized epidemiologic questionnaires at 2 time points, 1 year apart, further refines the categorization of people by diagnostic status. Third, the questionnaires permitted adjustment for physical health and the presence of comorbidities in statistical analyses. Fourth, the sample is fairly large and selected at random, with a high response rate (more than 75%) and a modest loss to follow-up (less than 20%).
At the same time, some limitations need to be acknowledged. First, the ESA study included a representative sample of community-living, French-speaking older adults in the province of Quebec, which excluded people living in the northern regions, residing in institutions, and the homeless. Therefore, the conclusions of our study may not apply to these groups, who usually exhibit different and more complex mental health problems and health service use. Second, we did not assess the interrater reliability of the ESA questionnaires. However, the interviewers were nurses who had experience in working with older adults and in the mental health field. The interviewers were also given a 2-day training course on interviewing techniques and how to use the computer-assisted ESA questionnaire, which included highly standardized procedures to minimize the potential for such biases. Third, the loss to follow-up was not at random; as found in other studies, those who did not participate in the follow-up interview, while similar to others on most variables, were more likely to report a lower income and were more likely to report a higher number of chronic conditions, which may be associated with a higher probability of psychiatric disorders. However, given that the participants who did not complete the second interview, as were respondents not covered under the public drug plan, were not more or less likely to report depression or anxiety during the first interview, results of the longitudinal cost analyses are less likely to be subject to follow-up bias. Fourth, our analyses of depression included both MDD and minor depression given the low numbers, and did not permit the reporting of ADrelated cost estimates for each separately. Additional analyses controlling for the presence of minor depression and MDD, although underpowered, showed almost identical results as those presented in Table 3 . 5 Finally, the results did not show important cost savings or decreased hospitalization costs associated with AD use for the treatment of depression and anxiety disorders. As recently concluded by Pan et al, 21 future studies should focus on further exploring the potential cost savings, if any, associated with different classes of ADs in the treatment of different clinical profiles of depression and anxiety in the older adult population, and on the potential for reducing costs by discontinuing use of ADs once depression has remitted.
